- Over 18-years at leading life sciences and strategy consulting
companies, including Revolution Medicines, Guardant Health,
Onyx Pharmaceuticals, and McKinsey & Company
SOUTH
SAN FRANCISCO, Calif., May 28, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, today announced that
Daniel A. Simon, will join the
company as its Chief Business Officer in August 2024.
"We are thrilled to welcome Daniel to IDEAYA Biosciences. His
extensive expertise in corporate strategy and business development
will be invaluable as we continue to build a leading global
precision medicine oncology company," said Yujiro S. Hata, President and Chief Executive
Officer of IDEAYA Biosciences. "We look forward to the insights he
will bring to help us achieve our strategic vision of delivering a
diversified first-in-class pipeline that addresses high unmet
medical needs in cancer."
"I am delighted to join IDEAYA Biosciences during this
significant phase of growth for the company, and to help build a
fully integrated biotechnology company," said Mr. Simon. "I look
forward to working with the accomplished team at IDEAYA to help
deliver their broad pipeline of programs for patients with
biomarker-defined cancers, including GNAQ/11, MTAP-deletion, HRD,
and MSI-high solid tumors."
Mr. Simon most recently served as Chief Business Officer at
Revolution Medicines from 2022 to 2024, and Senior Vice President,
BioPharma Business Development at Guardant Health from 2015 to
2022. Prior to Guardant, he served in corporate development
at Onyx Pharmaceuticals from 2012 to 2013, and as a consultant at
McKinsey & Company in the London office from 2006 to 2012, working in
the Pharmaceutical Practice. Mr. Simon earned his MBA with honors
from the Wharton School of the University of
Pennsylvania, and his M.A. Hons in Natural Sciences
from the University of Cambridge in the
United Kingdom.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to Mr. Simon's
impact on IDEAYA's business. IDEAYA undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's Annual Report on Form
10-K dated February 20, 2024 and any
current and periodic reports filed with the U.S. Securities and
Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-daniel-a-simon-as-chief-business-officer-to-lead-corporate-strategy-and-business-development-302155547.html
SOURCE IDEAYA Biosciences, Inc.